<html>
<head>
<title>Form 8-K
</title>
</head>
<body>




<hr size=3 noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br></b></font>
<font face="Times New Roman, Times, Serif" size=2>Washington, DC 20549</font>
</p>

<hr width=25% noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>FORM 8-K<br>
<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>CURRENT REPORT</b></font><br><font face="Times New Roman, Times, Serif" size=2><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=2>Date of Report&nbsp;&nbsp;(Date of earliest event reported):&nbsp;&nbsp;&nbsp;&nbsp;January 4, 2007</font><br></p>
<hr width=25% noshade>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>MILLENNIUM PHARMACEUTICALS, INC.</b></font><br><font face="Times New Roman, Times, Serif" size=2>(Exact name of registrant as specified in its charter)</font></p>
<table width=100% border=0 cellpadding=0 cellspacing=0 align=center>

<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>Delaware</b></font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>0-28494</b></font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>04-3177038</b></font></td>
</tr>
<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(State or other jurisdiction<br>of incorporation)</font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(Commission file number)</font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(IRS&nbsp;Employer<br>Identification&nbsp;No.)</font></td>
</tr>




</table>


<p align=center><font face="Times New Roman, Times, Serif" size=2><b>40 Landsdowne Street<br>Cambridge, Massachusetts 02139</b><br>
(Address of principal executive offices)&nbsp;(zip code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>(617)&nbsp;&nbsp;679-7000<br></b>
(Registrant's telephone number, including area code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>Not applicable<br></b>
(Former name or former address if changed since last report)</font></p>

<p align=left><font face="Times New Roman, Times, Serif" size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=94%><font face="Times New Roman, Times, Serif" size=2>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>




<hr size=3 noshade width=100%>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=top>

<td width=9%><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;2.02</b></font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2><b>Results of Operations and Financial Condition.</b></font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On January 4, 2007, Millennium
Pharmaceuticals, Inc. issued a press release to report selected unaudited financial
results for the year ended December 31, 2006 and to provide information about its goals
for 2007. The full text of the press release is attached to this Current Report on Form
8-K as Exhibit 99.1. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information in this Form 8-K
shall not be deemed &#147;filed&#148; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the Company&#146;s financial
position prepared in accordance with generally accepted accounting principles (GAAP). </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Specifically, the attached press
release discusses non-GAAP net income, non-GAAP profitability, non-GAAP
research and development expenses and non-GAAP selling, general and administrative
expenses which are non-GAAP financial measures. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $34 million in 2007, restructuring charges of between $15 million and $25
million in 2007 and stock-based compensation expense of between $30 million and $40
million in 2007, the Company is unable to provide a quantitative reconciliation because
the items that would be excluded are difficult to predict and estimate and are primarily
dependent on future events. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Company&#146;s management uses
these non-GAAP financial measures to supplement its understanding of the Company&#146;s
core operating results and future prospects, consistent with how management measures and
forecasts the Company&#146;s performance, especially when comparing such results to
previous periods or forecasts or to those of the Company&#146;s competitors. These
measures are also used by the Company&#146;s management in their financial and operating
decision-making and for compensation purposes. For example, while Company managers are
held accountable for most aspects of compensation expense within departmental budgets,
stock-based compensation expense is not included in the internal development, tracking or
evaluation of departmental budgets as reviewed by senior management. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>These non-GAAP measures exclude
certain non-operational and restructuring charges, non-cash charges and specified other
charges that are included in the most directly comparable GAAP measures. The Company
excludes these items to facilitate comparisons to historical operating results. The
Company believes that excluding these charges provides the users of financial statements
with important insight into the Company&#146;s operating results and related trends and
provides the users the opportunity to understand and analyze the Company&#146;s results in
a manner consistent with how management analyzes the results. Specifically, on both a
historic and a forward-looking basis, these non-GAAP measures exclude: </FONT></P>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=94%><font face="Times New Roman, Times, Serif" size=2>Expense associated with the amortization of acquisition-related intangible assets because
a significant portion of the purchase price for acquisitions may be allocated to
intangible assets that have lives of two to 13 years. Exclusion of the amortization
expense allows comparisons of operating results that are consistent over time for both the
Company&#146;s newly acquired and long-held businesses and with both acquisitive and
non-acquisitive peer companies. </font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Costs associated with the Company&#146;s restructuring efforts, such as reducing overhead
and consolidating facilities, resulting from the restructured relationship between
Schering-Plough and the Company for INTEGRILIN&reg; (eptifibatide) Injection and the
reduction in the Company&#146;s in-house research and development technologies and
personnel as well as associated general and administrative personnel and expenses. The
Company believes that the costs related to these restructuring activities are not
indicative of the Company&#146;s normal operating costs.</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
</table>

<p align=center><font face="Times New Roman, Times, Serif" size=2>2</font></p>
<hr size=3 noshade>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=94%><font face="Times New Roman, Times, Serif" size=2>
Expense associated with stock-based compensation related to stock options, the
Company&#146;s employee stock purchase plan and restricted stock because, while
stock-based compensation is a significant ongoing expense affecting the Company&#146;s
results of operations, the Company&#146;s management excludes stock-based compensation
from the Company&#146;s forecasting and planning process used to allocate resources in the
Company&#146;s ongoing portfolio prioritization efforts. Additionally, the Company
believes that excluding this expense could be helpful in comparing the Company&#146;s
financial results to previous periods because stock-based compensation charges are
excluded in the various operating expense categories. Finally, because of varying
available valuation methodologies, subjective assumptions and the variety of award types,
the Company believes that excluding stock-based compensation may enable useful comparisons
of the Company&#146;s operating results to its competitors.</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Termination payment, net of transaction expenses, associated with the Company&#146;s
receipt of a one-time payment resulting from the Company and AnorMED Inc.&#145;s mutual
agreement to terminate the Support Agreement between the parties. The Company believes
that the gain related to the termination fee received from AnorMED is not indicative of
the Company&#146;s normal revenues generated from its core operations.</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Costs associated with the Company&#146;s debt financing activities such as amortization on
capitalized professional and banking fees and charges related to the fair value of the put
premiums the Company has placed on its convertible notes because the Company considers
these costs to be nonoperational and nonrecurring and therefore not necessarily indicative
of the Company&#146;s future financial commitments. </font></td></tr>
</table>





<p align=center><font face="Times New Roman, Times, Serif" size=2>3</font></p>
<hr size=3 noshade>




<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b><a name="sig">SIGNATURE</a></b></font></p>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</font></p>




<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td colspan=2><font face="Times New Roman, Times, Serif" size=2>MILLENNIUM PHARMACEUTICALS, INC.<br>(Registrant)<br><br></font></td>
</tr>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>Date: January 4, 2007&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>By&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>/s/&nbsp;&nbsp;MARSHA H. FANUCCI</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2></font><hr noshade></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Marsha H. Fanucci</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Senior Vice President and Chief Financial Officer</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>4</font></p>
<hr noshade size=3>




<p><font face="Times New Roman, Times, Serif" size=2><b>EXHIBIT INDEX</b></font></p>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<th width=9% align=center colspan=2><font face="Times New Roman, Times, Serif" size=2>Exhibit No.<br></font><hr noshade></th>
<th width=3%>&nbsp;</th>
<th width=68% align=center><font face="Times New Roman, Times, Serif" size=2>Description<br></font><hr noshade></th>
<th width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></th>
</tr>
<tr valign=top>
<td width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=6%><font face="Times New Roman, Times, Serif" size=2>99.1</font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2>Press Release of Millennium Pharmaceuticals, Inc. dated January 4, 2007</font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr valign=top>
<td width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=6%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>5</font></p>





















</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "fm8k01042007.htm", "description": "FORM 8-K", "secsgml_size_bytes": 21641}]
{"company-data": {"conformed-name": "MILLENNIUM PHARMACEUTICALS INC", "cik": "0001002637", "assigned-sic": "2834", "irs-number": "043177038", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28494", "film-number": "07509845"}, "business-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139", "phone": "6176797000"}, "mail-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report  (Date of earliest event reported):    January 4, 2007
MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
0-28494
04-3177038
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
40 Landsdowne Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)
(617)  679-7000
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item   2.02
Results of Operations and Financial Condition.
On January 4, 2007, Millennium
Pharmaceuticals, Inc. issued a press release to report selected unaudited financial
results for the year ended December 31, 2006 and to provide information about its goals
for 2007. The full text of the press release is attached to this Current Report on Form
8-K as Exhibit 99.1.
The information in this Form 8-K
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the Company's financial
position prepared in accordance with generally accepted accounting principles (GAAP).
Specifically, the attached press
release discusses non-GAAP net income, non-GAAP profitability, non-GAAP
research and development expenses and non-GAAP selling, general and administrative
expenses which are non-GAAP financial measures. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $34 million in 2007, restructuring charges of between $15 million and $25
million in 2007 and stock-based compensation expense of between $30 million and $40
million in 2007, the Company is unable to provide a quantitative reconciliation because
the items that would be excluded are difficult to predict and estimate and are primarily
dependent on future events.
The Company's management uses
these non-GAAP financial measures to supplement its understanding of the Company's
core operating results and future prospects, consistent with how management measures and
forecasts the Company's performance, especially when comparing such results to
previous periods or forecasts or to those of the Company's competitors. These
measures are also used by the Company's management in their financial and operating
decision-making and for compensation purposes. For example, while Company managers are
held accountable for most aspects of compensation expense within departmental budgets,
stock-based compensation expense is not included in the internal development, tracking or
evaluation of departmental budgets as reviewed by senior management.
These non-GAAP measures exclude
certain non-operational and restructuring charges, non-cash charges and specified other
charges that are included in the most directly comparable GAAP measures. The Company
excludes these items to facilitate comparisons to historical operating results. The
Company believes that excluding these charges provides the users of financial statements
with important insight into the Company's operating results and related trends and
provides the users the opportunity to understand and analyze the Company's results in
a manner consistent with how management analyzes the results. Specifically, on both a
historic and a forward-looking basis, these non-GAAP measures exclude:
•
Expense associated with the amortization of acquisition-related intangible assets because
a significant portion of the purchase price for acquisitions may be allocated to
intangible assets that have lives of two to 13 years. Exclusion of the amortization
expense allows comparisons of operating results that are consistent over time for both the
Company's newly acquired and long-held businesses and with both acquisitive and
non-acquisitive peer companies.
•
Costs associated with the Company's restructuring efforts, such as reducing overhead
and consolidating facilities, resulting from the restructured relationship between
Schering-Plough and the Company for INTEGRILIN® (eptifibatide) Injection and the
reduction in the Company's in-house research and development technologies and
personnel as well as associated general and administrative personnel and expenses. The
Company believes that the costs related to these restructuring activities are not
indicative of the Company's normal operating costs.
2
•
Expense associated with stock-based compensation related to stock options, the
Company's employee stock purchase plan and restricted stock because, while
stock-based compensation is a significant ongoing expense affecting the Company's
results of operations, the Company's management excludes stock-based compensation
from the Company's forecasting and planning process used to allocate resources in the
Company's ongoing portfolio prioritization efforts. Additionally, the Company
believes that excluding this expense could be helpful in comparing the Company's
financial results to previous periods because stock-based compensation charges are
excluded in the various operating expense categories. Finally, because of varying
available valuation methodologies, subjective assumptions and the variety of award types,
the Company believes that excluding stock-based compensation may enable useful comparisons
of the Company's operating results to its competitors.
•
Termination payment, net of transaction expenses, associated with the Company's
receipt of a one-time payment resulting from the Company and AnorMED Inc.'s mutual
agreement to terminate the Support Agreement between the parties. The Company believes
that the gain related to the termination fee received from AnorMED is not indicative of
the Company's normal revenues generated from its core operations.
•
Costs associated with the Company's debt financing activities such as amortization on
capitalized professional and banking fees and charges related to the fair value of the put
premiums the Company has placed on its convertible notes because the Company considers
these costs to be nonoperational and nonrecurring and therefore not necessarily indicative
of the Company's future financial commitments.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
MILLENNIUM PHARMACEUTICALS, INC.
(Registrant)
Date: January 4, 2007
By
/s/  MARSHA H. FANUCCI
Marsha H. Fanucci
Senior Vice President and Chief Financial Officer
4
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release of Millennium Pharmaceuticals, Inc. dated January 4, 2007
5